https://www.selleckchem.com/pr....oducts/4-hydroxytamo
miR-103 expressed highly in PCOS and was positively related to IR. miR-103 inhibitor led to improved PCOS-related symptoms. In addition, miR-103 directly targeted IRS1, which was poorly expressed in PCOS, and IRS1 silencing promoted PCOS development. Furthermore, miR-103 regulated the PI3K/AKT pathway by targeting IRS1, and PI3K/AKT pathway suppression reduced the therapeutic effect of miR-103 inhibitor. This study indicates that miR-103 disrupts the PI3K/AKT pathway activation by targeting IRS1, thereby aggr
Like
Comment
Share
